# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Duke Kahanamoku (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML050-SYN
- Date: 2026-09-28
- Fictional facility: St. Posthumous Health Center
- Fictional author: Kawika Lindgren-Morrison, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Six-month review: repeat echocardiogram and the defibrillator decision. **S**

## History of present illness

Mr. Kahanamoku returns two weeks after his annual wellness visit; at his wish, members of his ʻohana joined him for the defibrillator discussion. He completed all 36 sessions of cardiac rehabilitation in the summer, swam in the pool there for the last month, and now swims three mornings a week in calm water inside the reef with a friend; he has not surfed big waves. He has had no swelling, orthopnea, palpitations, lightheadedness or fainting. The planned increase of sacubitril-valsartan two weeks after his last review did not happen: the nurse called, but he put off the laboratory visit twice because of work, the call was not repeated, and he stayed on the starting dose. He takes every dose of his medicines. Today's echocardiogram shows the ejection fraction has risen from 30% to 38%. **S**

| Element | Detail |
|---|---|
| Rehabilitation | All 36 sessions completed |
| Activity | Swims three mornings a week in calm water with a companion |
| Missed step | Sacubitril-valsartan increase and its laboratory check did not happen |
| Echocardiogram | Ejection fraction 38%, from 30% |
| KCCQ-12 | 80, from 38 at intake |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Cardiovascular | Negative | No chest pain, palpitations, fainting or ankle swelling |
| Respiratory | Negative | Breathless only swimming hard against a current |
| Neurological | Negative | No lightheadedness |

3 systems reviewed. **S**

## Current medications

- Aspirin 81 mg delayed-release oral tablet, one tablet daily **S**
- Atorvastatin 80 mg oral tablet, one tablet daily **S**
- Furosemide 20 mg oral tablet, one tablet every morning **S**
- Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice daily **S**
- Carvedilol 12.5 mg oral tablet, one tablet twice daily with food **S**
- Empagliflozin 10 mg oral tablet, one tablet daily; hold on days of vomiting, diarrhea or not eating or drinking **S**
- Spironolactone 25 mg oral tablet, one-half tablet (12.5 mg) daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 106/66 mmHg; pulse 64 bpm; respirations 16/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 92.8 kg; BMI 27.1 kg/m². All vital signs are synthetic.

NT-proBNP: 620 pg/mL (high); Sodium: 138 mmol/L; Potassium: 4.6 mmol/L; Creatinine: 1.14 mg/dL; eGFR (CKD-EPI 2021): 70 mL/min/1.73 m²; Glucose: 95 mg/dL; Magnesium: 2 mg/dL; Hemoglobin: 14.1 g/dL; Ferritin: 248 ng/mL; Transferrin saturation: 27%; LVEF by echocardiogram: 38% (low); KCCQ-12 overall summary: 80. All results are synthetic.

## Change since baseline

- NT-proBNP: 2450 pg/mL (high) at baseline, 620 pg/mL (high) at this visit **S**
- Sodium: 138 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4.2 mmol/L at baseline, 4.6 mmol/L at this visit **S**
- Creatinine: 1.02 mg/dL at baseline, 1.14 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 81 mL/min/1.73 m² at baseline, 70 mL/min/1.73 m² at this visit **S**
- Glucose: 102 mg/dL (high) at baseline, 95 mg/dL at this visit **S**
- Magnesium: 2 mg/dL at baseline, 2 mg/dL at this visit **S**
- Hemoglobin: 13.4 g/dL at baseline, 14.1 g/dL at this visit **S**
- Ferritin: 62 ng/mL (low) at baseline, 248 ng/mL at this visit **S**
- Transferrin saturation: 16% (low) at baseline, 27% at this visit **S**
- KCCQ-12 overall summary: 38 at baseline, 80 at this visit **S**

## Immunizations given today

- Recombinant zoster vaccine, dose 1 of 2 **S**
- Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 106/66, pulse 64; weight 92.8 kg |
| Orthostatic vital signs | Standing at three minutes 104/64 mmHg without symptoms |
| Neck | Jugular venous pressure not raised |
| Cardiovascular | Regular rhythm; soft apical systolic murmur; no S3 |
| Respiratory | Clear |
| Extremities | No edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Heart failure with reduced ejection fraction** (I50.22). Much better: NYHA class I to II, KCCQ-12 80, NT-proBNP 620 pg/mL from 2,450, and an ejection fraction of 38% from 30% after more than five months on all four classes. Potassium 4.6 mmol/L and creatinine 1.14 mg/dL (eGFR 70). Sacubitril-valsartan is still at the starting dose because a titration step was missed. **S**
   - Raise sacubitril-valsartan to 49/51 mg twice daily today; standing blood pressure 104/64 without symptoms allows it.
   - Metabolic panel in one to two weeks, drawn at the clinic, with nurse calls for further steps.
   - Continue carvedilol 12.5 mg twice daily, empagliflozin, spironolactone 12.5 mg and furosemide 20 mg.
2. **Defibrillator decision** (I50.22). The ejection fraction is 38%, above the 35% threshold, after more than 90 days of therapy and years after the infarction, so a primary-prevention ICD is not indicated. QRS 104 ms, so no CRT. He and his ʻohana were told what would change this. **S**
   - Repeat echocardiogram if symptoms worsen or after further titration if his course changes.
   - Call 911 for fainting or a racing heartbeat.
3. **Iron deficiency** (E61.1). Repleted: ferritin 248 ng/mL, transferrin saturation 27%, hemoglobin 14.1 g/dL. **S**
   - Iron studies yearly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure and heart rate (seated and standing) | Every visit | Completed today | 106/66 mmHg, pulse 64; standing 104/64 without symptoms |
| Examination | Weight, volume status (jugular venous pressure, edema, lungs) and NYHA class | Every visit | Completed today | 92.8 kg; jugular venous pressure not raised; no edema; NYHA I to II |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | One to two weeks after a dose change | Deferred | The panel due one week after the planned sacubitril-valsartan increase was never drawn, because the increase itself did not happen: he put off the laboratory visit twice for work and the nurse's call was not repeated. No laboratory harm resulted (potassium 4.6, creatinine 1.14 today), but the ARNI stayed at the starting dose for about five months, which may have limited his recovery. Corrective action: laboratory tests drawn at the clinic on the day of each change or by the nurse at home, and nurse calls that continue until each step is done |
| Laboratory | Metabolic panel (sodium, potassium, creatinine and eGFR) and magnesium | Every three to six months when stable | Completed today | Sodium 138, potassium 4.6, creatinine 1.14 mg/dL (eGFR 70), magnesium 2.0 |
| Medication safety | Guideline-directed medical therapy: ARNI, evidence-based beta-blocker, MRA and SGLT2 inhibitor, toward target doses | Every two weeks during titration | Completed today | Sacubitril-valsartan raised to 49/51 mg today; panel in one to two weeks |
| Imaging | Echocardiogram | At diagnosis; repeat after three to six months of optimized therapy for device decisions, or with unexplained change | Completed today | After more than 90 days of therapy: ejection fraction 38% (from 30%), end-diastolic diameter 58 mm, mild mitral regurgitation |
| Examination | Primary-prevention ICD evaluation (and CRT if QRS is wide) | After at least 90 days of optimized therapy, and at least 40 days after a myocardial infarction | Not indicated | Ejection fraction 38%, above 35%; QRS 104 ms; no ICD or CRT now |
| Laboratory | NT-proBNP | At diagnosis; selectively for prognosis (not for titration) | Completed today | 620 pg/mL, from 2,450, for prognosis |
| Medication safety | Iron studies (ferritin, transferrin saturation) and intravenous iron | At diagnosis; after repletion and about yearly | Completed today | Ferritin 248 ng/mL, transferrin saturation 27%, hemoglobin 14.1 g/dL |
| Survey | KCCQ-12 heart failure health status | At diagnosis, then every three to six months | Completed today | 80 |
| Laboratory | Lipid panel | Every three to twelve months when stable | Up to date | LDL 62 mg/dL in the spring |
| Survey | Depression screen (PHQ-2, then PHQ-9 if positive) | Periodically | Up to date | PHQ-2 0 at the wellness visit |
| Referral | Cardiac rehabilitation for heart failure | When eligible: ejection fraction 35% or below, NYHA II to IV, six weeks of stable therapy and no procedure in six weeks | Completed today | All 36 sessions completed in the summer; swimming in calm water with a companion |
| Examination | Vaccinations (pneumococcal, influenza, COVID-19, RSV) | Yearly or per schedule | Completed today | Influenza, RSV and COVID-19 at the wellness visit; PCV20 in the spring; zoster dose 1 and Tdap today |
| Self-management | Self-care: daily weights, sodium, sick-day rules and symptoms to report | Every visit | Completed today | Daily weights; ocean plan followed; sick-day card kept in his wallet |
| Self-management | Culturally safe care: ʻohana involvement as he chooses; his own healing practices | Every visit | Completed today | ʻOhana included in the defibrillator discussion, as he asked at the wellness visit |

## Goal progress

- Euvolemia: no ankle swelling or orthopnea, with a steady dry weight. Outcome by 2026-04-27: Dry weight about 93 kg; no edema or orthopnea; furosemide reduced to 20 mg. **S**
- All four guideline-directed medicines at the highest doses he tolerates within three months. Outcome by 2026-09-28: All four classes started within two weeks of diagnosis; carvedilol 12.5 mg twice daily, empagliflozin and spironolactone at their doses; sacubitril-valsartan stayed at the starting dose for five months after a missed titration step and was raised at six months. **S**
- KCCQ-12 at least 20 points higher and NYHA class I to II within six months. Outcome by 2026-09-28: KCCQ-12 38 to 80; NYHA class I to II. **S**
- Back in the ocean safely, swimming in calm water with a companion. Outcome by 2026-09-28: Swimming three mornings a week in calm water inside the reef with a friend, after cardiac rehabilitation. **S**
- LDL cholesterol below 70 mg/dL. Outcome by 2026-04-27: LDL 62 mg/dL on atorvastatin 80 mg. **S**

## Medication changes

- Stopped: Sacubitril 24 mg / valsartan 26 mg oral tablet, one tablet twice daily, first dose 36 hours after the last lisinopril **S**
- Started: Sacubitril 49 mg / valsartan 51 mg oral tablet, one tablet twice daily **S**

## Guideline basis

- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022), American Heart Association, American College of Cardiology, and Heart Failure Society of America (Circulation 2022;145(18):e895-e1032)
- 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction (2024), American College of Cardiology (J Am Coll Cardiol 2024;83(15):1444-1488)
- 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (2017), American Heart Association, American College of Cardiology, and Heart Rhythm Society (Circulation 2018;138(13):e272-e391)
- CMID: Clinical Monitoring Intelligence Database, heart failure and ischemic heart disease monographs (2026), Aether Forge
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Zoster dose 1 and Tdap given today; second zoster dose in two to six months. Metabolic panel at the clinic in one to two weeks, with the nurse's call. Review in three months. Cardiology review in six months. Call 911 for chest pain, fainting or a racing heartbeat. **S**

